Author Archives: Marisa Wexler MS

AbbVie Takes Charge of Potential IPF Therapies From Morphic Therapeutic

AbbVie will assume development of Morphic Therapeutic‘s alpha v beta 6 (αvβ6) integrin inhibitors as potential treatments for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, exercising a licensing option under an earlier research partnership between the companies. Integrins control a wide variety of cellular processes, including…

Early Data Support Ability of MicroRNA Mimic, MRG-229, to Treat IPF

New preclinical data support MRG-229, an investigative next-generation treatment for idiopathic pulmonary fibrosis (IPF), as safe and effective, miRagen reported. “We believe this body of evidence supports further development of MRG-229 as a potentially differentiated approach for the treatment of IPF,” William S. Marshall, PhD, the company’s president and CEO, said in…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums